Introduction
Although lithium is regarded as being the first-choice drug for both acute treatment and prophylaxis of bipolar disorder. it appears to be ineffective in many cases-either due to noncompliance due toside effects, or because ofresistance, especially i n mixed states and rapid cycling (Calabrese et al., 1997) . I n these patients, antiepileptic drugs such as carbamazepine and valproate represent a viable alternative or a useful adjunctive therapy (Frances et al., 1996) . Recently, several open studies (McElroy et al., 1997; Schafler et al., 1997 : ErJffurth et al., 1998 : Knoll et al.. 1998 Young, 1998) case series (Marcotte, 1997; Chaemi et al., 1998) . and single case reports (Rybackand Ryback, 1995; Stanton et dl., 1997; Soutullo et al.. 1998) have suggested that the new antiepileptic drug gabapentin, which has proved effective i n the treatment refractory partial seizures and secondary generalized tonic-clonic seizures, might also be effective in bipolar disorder. Preliminary clinical evidence also suggests it has anxiolytic properties that may be useful i n the treatment of panic disorder (Pollack et dl.. 1998 ) and social phobia (Pande et dl.. 1997 ).
Due to its unique pharmacokinetics. gabapentin appears to have no drug interactions and a better profile i n terms of safety and tolerability than traditional antiepileptic drugs (McLean, 1995; Ramsay, 1995) . Forthis reason,gabapentin may provided promising therapeutic option for bipolar patients who are resistant or intolerant to tradjtional mood stabilizers. So far. little information regardjng the efficacy of gabapentin i n the treatment of bipolar disorder has been made available, and what there is has been derived from restricted samples (Table 1) . Obviously, these reports are very preliminary, and the efficacy of gabapentin needs to be confirmed in controlled studies on larger populations. In achieving this aim, however. several methodological obstacles need to be overcome. Controlled clinical trials are not feasible i n many cases of manic or mixed states, for a variety of reasons-such as the severity of the symptoms, the presence of psychotic features, impaired judgment and impulsive changes i n consent, and the difficulty of establishing outcome criteria and evaluating changes in symptoms as regards day-to-day or within-day fluctuations i n mood. Similarly, severely depressed or mixed patients with suicidal tendencies cannot be enrolled i n randomized controlled pharmacological trials. In these cases, information must Cl~n~cal Experience Usinq Adiunctive Gabapentin in Treatment-Resistant Bipolar Mixed States Pharrnacopsychiat. 32 (1999) Table 2 , the patients had been inadequately responsive to at least one standard mood stabilizer, despite receiving optimized regimens that had been stable for at ieast eight weeks. Table 2 also summarizes the predominant types of residual symptom.
The semistructured interview for mood disorder (SLMD) (Cassano et al., 1987) was used to ensure that the diagnostic criteria were met. This tool collects demographic information, patient history, and clinical information in a systematic way, and explores the presence of the DSM-111-R criteria for a major depressiveepisode and mania.The SIMD was developed as part of the Pisa-Memphis (now San Diego) collaborative study on affective disorders, and its overall reliability and usefulness in diagnostic assessment have been documented elsewhere (Cassano et al., 1989; Perugi et al., 1990; Perugi et al., 1997) . Each patient was assessed at all visjts by the same physician, who also took the treatment decisions. All patients provided informed consent to participation in the clinical evaluations and treatment regimens.
Cabapentin was administered as an add-on therapy for a period of eight weeks, in combination with other mood stabilizers, antidepressants, neuroleptics, or benzodiazepines. The initial dosage of gabapentin was 300 mglday; this was later increased to 2000mg/day, depending on the clinical response and occurrence of significant side effects. Doses and adverse effects were recorded at each visit.
Psychopathological assessment was conducted at the beginning and end of the observation period using the Hamilton Rating Scale for Depression (HRSD) (Hamilton. 1967), the Young Mania Rating Scale (YMRS) (Young et al., 1978) and clinical global impression (CGI) (Guy. 1976) . A final CGI improvement scale score of 1 indicated marked improvement (virtual remission of symptoms and return to normal functioning); a score of 2 indicated moderate improvement (significant reduction of symptoms and clearly improved social or vocational functioning); a score of 3 indicated minimum improvement (slight symptomatic and/or functional improvement); a score of 4 indicated no response: and a score of 5 indicated worsening of symptoms (or discontinuation). Patients who responded to gabapentin add-on treatment after eight weel6 were subsequently seen monthly (or more frequently if needed) for a period ranging from 4 to 12 months, to assess the stability of the response and identify any side effects.
Results
Adjunctive gabapentin was well tolerated by most patients; only one had to interrupt the drug treatment, due to irritability and ataxia. He was taking gabapentin in combination with valproic acid (1500 mg/day). clonazepam (4 mglday) and perphenazine (16 mgjday). In the remainder of the patients. the most common side effects were sedation ( n = 9 , 45%), irritability ( n = 5,25%), tremor (n =4,20%), nausea ( n = 3.15 %), and ataxia or motor instability (n = 3.15 %).These effects did not produce any clinically relevant impairment, usually occurred when the gabapentin dosage was increased, and tended to diminish with time.
Of the 20 patients who completed eight weeks of treatment. 10 were regarded as responders: fourwith a CGI scoreof 1 (marked improvement) and six with a CGI score of 2 (moderate improvement). Nine patients were regarded as nonresponders: seven with a CGI score of 3 (minimum improvement), and two with a CCI score of 4 (no change). The mean (& SD) dose of gabapentin at week 8 was 1130 k361.4 mg (range 600-2000).
The mean HRSD score showed an equally marked reduction. from 18.2 (SD = 6.97) to 10.6 (SD = 6.51); thedifference between the initial and final mean scores was statistically significant ( t = 5.73, P = 0.0001). In addition. the mean YMRS score showed a reduction from 9.7 (SD =5.71) to 7.2 (SD=3.75), but this difference was not statistically significant ( t = 1.83. P = n.s.). When the scores of the nine patients with more severe mixed manic residual symptomatology were analyzed. the mean HRSD score was found to have decreased from 17.0 (SD = 8.65) to 6.4 (SD = 4.31 ; t = 4.51. P = 0.003), while the mean YMRS score decreased from 14.6 (SD = 5.48) to 11.1 (SD = 3.68; t = 1.60, P = n.s.).
Of the 10 patients who were judged to be responders after eight weeks, nine maintained symptomatic remission over a subsequent period of time ranging from 4 to 12 months, without clinically relevant side effects or adverse events. During this period, it was possible to reduce and withdraw antidepressants in two patients (nos. 2 and 7), and in three cases (nos. 3,6, and 18) to reduce neuroleptics. Patient 19 discontinued gabapentin and required addition of neuroleptics after three months, due to exacerbation of manic symptoms.
Discussion
The pharmacological treatment of patients with bipolar mixed states has received little attention, despite the high prevalence of such conditions (McElroy et al., 1997) . The patients are often severely ill, requiring hospitalization or day care, and are often resistant to treatment (Pemgi et al., 1997) . The results of the present study are encouraging in this regard; gabapentin appears to be an effective adjunctive treatment for drugresistant bipolar mixed states. In particular, gabapentin seems to have antidepressant properties, improving global function-
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Pharrnacopsychiat. 32 (1999) 139 ing and reducing depressive symptoms in at least 50% of the defined, at least in the present sample. Only two patients patients. The mast common response was a reduction in presented with predominantly manic symptoms; it was theresymptoms to more tolerable levels. This improvement in fore unlikely that an antimanic effect could be demonstrated in depression occurred irrespective of the initial severity of the this sample. However, in contrast to previous reports(Shortand mania score. By contrast, manic symptoms did not improve to Cooke, 1995; Ghoemi et a]., 1998). none of the patients in the any significant extent. We would tentatively conclude that the present study reported any worsening of manic symptoms or antimanic properties of gabapentin appear to be less well increasing cyclicity. Obviously, the present study has several limitations. As in other investigations, the sample is a restricted one, and the period of observation is too short. Long-term studies are necessary to provjde a more precise definition of the mood-stabilizing effects of gabapentin. The major weakness of the data presented here is the lack of a control group. However, a placebo response or spontaneous remissions must be regarded as unlikely, since all of the patients had a history of a severe, long-lasting, continuous, drug-resistant symptoms. Future placebo-controlled studies capable of specifically assessing the potential antidepressant properties of gabapentin would be ofvalue. This is important not only for methodological reasons. but because depressive symptoms in bipolar patients represent a major challenge.
